Drug screening using reprogramming resistance to overcome resistance to ALK-targeted therapy

被引：0
|
作者：
Utsumi, Takahiro [1 ]
Uchibori, Ken [2 ]
Nishio, Makoto [2 ]
Yamada, Yasuhiro [3 ]
Okamoto, Isamu [4 ]
Katayama, Ryohei [1 ]
机构：
[1] JFCR, Canc Chemother Ctr, Div Exp Chemother, Tokyo, Japan
[2] JFCR, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-1010
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [1] Resolving resistance to ALK-targeted therapy
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2016, 13 (2) : 65 - 65
  • [2] Trials to overcome drug resistance to EGFR and ALK targeted therapies past, present, and future
    Spaans, Johanna N.
    Goss, Glenwood D.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [3] Acquired resistance to targeted drugs and novel therapy to overcome the resistance
    Yano, Seiji
    ANNALS OF ONCOLOGY, 2017, 28 : 70 - 70
  • [4] Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
    Kyi, Chrisann
    Friedman, Claire F.
    Mueller, Jennifer J.
    Benayed, Ryma
    Ladanyi, Marc
    Arcila, Maria
    Yang, Soo Ryum
    Hensley, Martee L.
    Chiang, Sarah
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
  • [5] ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
    Ye, Mingxiang
    Zhang, Xinxin
    Li, Nan
    Zhang, Yong
    Jing, Pengyu
    Chang, Ning
    Wu, Jianxiong
    Ren, Xinling
    Zhang, Jian
    ONCOTARGET, 2016, 7 (11) : 12289 - 12304
  • [6] ALK-targeted therapy for poor-prognosis childhood cancers
    Moreno, Lucas
    LANCET ONCOLOGY, 2013, 14 (06): : 439 - 440
  • [7] Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance
    Nguyen, Ngoc Minh
    Cho, Jungsook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [8] Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
    Okada, Koutaroh
    Araki, Mitsugu
    Sakashita, Takuya
    Ma, Biao
    Kanada, Ryo
    Yanagitani, Noriko
    Horiike, Atsushi
    Koike, Sumie
    Oh-hara, Tomoko
    Watanabe, Kana
    Tamai, Keiichi
    Maemondo, Makoto
    Nishio, Makoto
    Ishikawa, Takeshi
    Okuno, Yasushi
    Fujita, Naoya
    Katayama, Ryohei
    EBIOMEDICINE, 2019, 41 : 105 - 119
  • [9] ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time
    Husain, Hatim
    Rudin, Charles M.
    ONCOLOGY-NEW YORK, 2011, 25 (07): : 597 - 601
  • [10] Network Medicine to Overcome Drug Resistance in CRPC or NEPC: Drug Efficacy Reprogramming
    Kosaka, Takeo
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 153 - 153
12345